La leucémie aiguë peu différenciée (MO) aspects hématologiques, immunophénotypiques, cytogénétiques, incidence pronostique

No recurent cytogenetic specific abnormalities were described in AMLO but a few of them are more frequent in this pathology (trisomies 8 and 13, monosomies 5 and 7, anomalities of chromosome 11). The clinical outcome is specially poor with a high mortafity (> 50 %) one year after diagnosis. Research about intraceflular modifications of AMLO blast cells could and would lead to ameliorate the follow-up of patients and certainly help to the emergence of new treatments. Acute myeloid leukaemia with minimal differentiation - AMLO - retrospective study - prognostic factors.